Nieuws en video's - BIOTECHNOLOGY

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We’ve successfully executed many important milestones, including raising approximately $250 million through two equity...

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM, Mass. , Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced Spyre has been added to the Nasdaq...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market ® (NASDAQ ® ) that are classified as either biotechnology or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA PR Newswire NEW YORK, Dec. 3, 2024 NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sana and certain of its officers...

PALO ALTO, CA / ACCESSWIRE / November 26, 2024 / Bioz, Inc ., an innovator of AI-powered scientific citation management services, is proud to announce its continued partnership with Gold Biotechnology , a highly respected leader in the field of biological research products. Having collaborated for several years, GoldBio has successfully integrated Bioz's advanced solutions, including Bioz Badges and the Bioz Content Hub, to enhance their visibility and user engagement across the global research...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA PR Newswire NEW YORK, Nov. 25, 2024 NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sana and certain of its officers...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sana and certain of its officers...

Tsingke Successfully Showcases Innovations at BIO-Europe 2024 PR Newswire BEIJING, Nov. 12, 2024 BEIJING , Nov. 12, 2024 /PRNewswire/ -- Tsingke proudly concluded its participation in BIO-Europe 2024, held from November 4 to 6 in Stockholm, Sweden . As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees join, representing more than 2,800 companies and over 60 countries. At the event, Tsingke showcased its innovative products and...

In this interview, we speak with Ailsa Craig and Marek Poszepczynski, portfolio managers at International Biotechnology Trust ......

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors. The Bio-dollar value of the...

dBio Partners with Japan's Tamana City to Lead the Future of Smart Healthcare Solutions PR Newswire TAIPEI, Sept. 10, 2024 TAIPEI , Sept. 10, 2024 /PRNewswire/ -- Decentralized Biotechnology Intelligence Co., Ltd (dBio), a global leader in exercise and health platform solutions, has announced a significant milestone in its international expansion. In a strategic move to address Japan's pressing demographic challenges, dBio has signed a Memorandum of Understanding (MOU) with the government of...

CALGARY, AB / ACCESSWIRE / August 22, 2024 / ASIA GREEN BIOTECHNOLOGY CORP. (CSE: ASIA) (" Asia Green " or the " Company ") is pleased to announce that it has entered into a non-binding letter of intent (" LOI ") dated August 22, 2024 to acquire all of the issued and outstanding common shares of Paladin Services Group Ltd. (" Paladin "), a private company that owns a Class II Disposal Well in the Bonnie Glen field area of central Alberta and which has secured disposal commitments from several...

CALGARY, AB / ACCESSWIRE / August 21, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announced today that it has elected to the terminate the previously announced agreement dated February 9, 2024, pursuant to which the Company was to acquire all of the issued and outstanding shares in two private companies being Burton Growers Ltd. and Green-Sight Agri-Holdings Inc. Management of Asia Green has cited delays in obtaining regulatory approval and the ongoing impact of other...

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor Summit Date: August 20 th , 2024 Presentation Time: 2:00 pm ET Location: https://www.webcaster4.com/Webcast/Page/3062/51117 The theme...

Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics will participate in a fireside chat at the BTIG Virtual...

J.P. Morgan Life Sciences Private Capital Closes Inaugural Biotechnology Venture Capital Fund with over $500 million in Commitments PR Newswire NEW YORK, June 13, 2024 NEW YORK , June 13, 2024 /PRNewswire/ -- J.P. Morgan Private Capital, a venture capital and growth equity investment team within J.P. Morgan Asset Management, today announced the final close of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I (the "Fund") , led by Chief Investment Officer...

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / May 24, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the "Documents") on SEDAR: the Company's Annual Audited Financial Statements for the year ended December...

Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector PR Newswire MIAMI, May 15, 2024 MIAMI , May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC ( https://geneticnetworks.com/ ), a leader in applied molecular biology and drug development. Effective May 15, 2024 , the LOI signifies...

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / May 10, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the Alberta Securities Commission ("ASC") on May 08, 2024, remains in effect. The MCTO prohibits the CEO and CFO of the Company from trading in the...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, AB / ACCESSWIRE / May 8, 2024 / Asia Green Biotechnology Corp. (" Asia Green " or the " Company ") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024 and April 26, 2024, the Alberta Securities Commission ( "ASC" ) has granted the Company's application for the issuance of a Management Cease Trade Order (" MCTO "). The MCTO prohibits the CEO and CFO of the Company from trading in the...